Roble Belko & Company’s Immunogen Inc IMGN Stock Holding History

Roble Belko & Company’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,000	Closed	-$5K	–	342
2022 Q4	$5K	Buy	+1,000	New	+$5.42K	﹤0.01%	273

Other funds holding IMGN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Roble Belko & Company's IMGN Position: Q1 2023 in Review

Roble Belko & Company sold out of Immunogen Inc (IMGN) in Q1 2023, closing a stake of 1,000 shares — an estimated $5K sold.

Roble Belko & Company first reported a position in IMGN in Q4 2022 and held it in 1 quarter. The position peaked at $5K in Q4 2022. 190 funds tracked by Wall St. Rank hold IMGN as of Q1 2023.

Roble Belko & Company reported no remaining Immunogen Inc position as of Q1 2023 after selling out during the quarter.
Roble Belko & Company sold 1,000 Immunogen Inc shares in Q1 2023, an estimated $5K.
Roble Belko & Company first reported a position in Immunogen Inc in Q4 2022 and held it in 1 quarter.
Roble Belko & Company's Immunogen Inc position peaked at $5K in Q4 2022.
190 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2023.

Based on Roble Belko & Company's 13F filing for Q1 2023, filed 10 May 2023.